Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
详细信息 查看全文
- 作者：Betü ; l Oran1 ; boran@mdanderson.org" class="auth_mail" title="E-mail the corresponding author ; Jorge Cortes2 ; Amer Beitinjaneh3 ; Hsiang-Chun Chen4 ; Marcos de Lima5 ; Keyur Patel6 ; Farhad Ravandi2 ; Xuemei Wang4 ; Mark Brandt2 ; Borje S. Andersson1 ; Stefan Ciurea1 ; Fabio P. Santos2 ; Leandro de Padua Silva1 ; Elizabeth J. Shpall1 ; Richard E. Champlin1 ; Hagop Kantarjian2 ; Gautam Borthakur2
- 关键词：AML ; FLT3-ITD mutation ; Allogeneic stem cell transplantation ; Postremission therapy
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：22
- 期：7
- 页码：1218-1226
- 全文大小：596 K
文摘
- •
HSCT in AML with FLT3-ITDmut as postremission therapy in CR1 is associated with longer relapse-free survival and overall survival compared with consolidation chemotherapy.
- •
Irrespective of postremission therapy, relapse remains the main reason for treatment failure.
- •
Innovative transplantation approaches to improve relapse incidence are urgently needed.